British Journal of Clinical Pharmacology · 1998 · 25 citations · 8 references
MedicinePharmacokineticsPharmacologyBioavailabilityNeuropharmacologyPharmacodynamicsDopaminergic PharmacologyDrug DispositionFood Effects On BioavailabilityFood Effects On Oral AbsorptionParkinson DiseaseParkinsonian DisordersAgonist ActivityDopamine PharmacokineticsNutrition In Parkinson's DiseaseParkinson's Disease PharmacotherapyParkinson’s Disease PharmacotherapyParkinson’s Disease TreatmentPharmacokinetics In Neurodegenerative Disease
AIMS: Ropinirole is a specific non-ergoline dopamine D2-receptor agonist with antiparkinsonian properties. The pharmacokinetic parameters of ropinirole taken in the fasted condition were compared with those when it was co-administered with food. METHODS: This was an open, randomized, two sessions cross over study in 12 patients with Parkinson's disease, comparing the steady-state pharmacokinetic profiles of ropinirole on two different study days: 'fasted' and 'fed'. RESULTS: The mean Cmax was lower in the 'fed' regimen than in the 'fasted' one (-25%, P=0.002). The median tmax was observed 2.6 h later in the 'fed' regimen than in the 'fasted' regimen (P<0.05). There was a slight but significant decrease in AUC(0,8 h) in the 'fed' regimen (P=0.03). CONCLUSIONS: Food decreases the rate of absorption of ropinirole, but has little effect on the extent of absorption.
8
Margaret M. Hoehn, Melvin D. Yahr · Neurology · 1967 · 12K citations · Full text
Overdependence on degraded gist memory in Alzheimer's disease.
Neuropsychology · 2006 · 4.7K citations
Active Transport of L-Dopa in the Intestine
D. N. Wade, P. T. Mearrick, Janet Morris · Nature · 1973 · 157 citations